Deciphera begins Phase III of GIST candidate

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) began the Phase III INVICTUS trial of DCC-2618 to treat gastrointestinal stromal tumors (GIST).

The double-blind, U.S. study will

Read the full 226 word article

User Sign In